静脉戈利木单抗治疗多关节型幼年特发性关节炎的开放标签3期研究
这项开放标签3期研究评估了静脉戈利木单抗治疗活动性多关节型幼年特发性关节炎(pc-JIA)的疗效、药代动力学(PK)和安全性。127例患儿接受80 mg/m2戈利木单抗治疗,第28周JIA ACR 30/50/70/90应答率分别为84%/80%/70%/47%,并维持至第52周;PK暴露在各年龄组一致且与成人2 mg/kg剂量相当,抗体阳性率31%,严重感染发生率6%。
要点
- 静脉戈利木单抗按体表面积给药在pc-JIA患儿中耐受良好,并提供足够PK暴露支持临床疗效。
- 第28周JIA ACR 30/50/70/90应答率分别为84%/80%/70%/47%,并维持至第52周。
- 戈利木单抗抗体阳性率31%,中和抗体阳性率19%,抗体阳性者中位 trough 浓度较低。
核心结论
- 按体表面积给药的静脉戈利木单抗在活动性pc-JIA患儿中耐受良好,并提供足够的PK暴露以支持临床疗效。
研究设计与样本
- 开放标签3期研究,纳入2至<18岁、尽管接受MTX治疗≥2个月仍为活动性pc-JIA的患儿。
- 患儿接受80 mg/m2静脉戈利木单抗在第0、4周给药,之后每8周一次至第52周,并每周联用MTX至第28周。
- 共127例患儿接受静脉戈利木单抗治疗;主要终点为第28周PK暴露,主要次要终点为第52周模型预测的稳态8周给药间期AUC(AUCss)。
主要发现
- 第28周JIA ACR 30、50、70、90应答率分别为84%、80%、70%、47%,并维持至第52周。
- 第28周戈利木单抗血清浓度为0.40 µg/ml,AUCss为399 µg·day/ml;PK暴露维持至第52周。
- 稳态 trough 戈利木单抗浓度和AUCss在各年龄组间一致,并与成人类风湿关节炎静脉戈利木单抗2 mg/kg剂量相当。
- 通过高灵敏度耐药物检测法,戈利木单抗抗体阳性率为31%(39/125),中和抗体阳性率为19%(24/125);抗体阳性患者的中位 trough 戈利木单抗浓度低于抗体阴性患者。
- 严重感染报告率为6%,包括一例因感染性休克死亡。
关键数值与推荐
- JIA ACR 30、50、70、90应答率在第28周分别为84%、80%、70%、47%。
- 第28周戈利木单抗血清浓度0.40 µg/ml,AUCss 399 µg·day/ml。
- 戈利木单抗抗体阳性率31%(39/125),中和抗体阳性率19%(24/125)。
- 严重感染发生率6%,包括一例死亡。
临床怎么用
- 对于活动性pc-JIA且MTX治疗≥2个月仍活动患儿,可考虑按体表面积80 mg/m2静脉戈利木单抗每8周给药(第0、4周后)。
- 治疗期间应监测抗体形成,抗体阳性者 trough 浓度较低,可能影响疗效。
- 需警惕严重感染风险,本研究中严重感染发生率为6%,包括一例感染性休克死亡。
局限性
- 本研究为开放标签设计,无对照臂。
- 样本量有限(127例),长期安全性数据未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess efficacy, pharmacokinetics (PK) and safety of intravenous (i.v.) golimumab in patients with polyarticular-course JIA (pc-JIA). METHODS: Children aged 2 to <18 years with active pc-JIA despite MTX therapy for ≥2 months received 80 mg/m2 golimumab at weeks 0, 4, then every 8 weeks through week 52 plus MTX weekly through week 28. The primary and major secondary endpoints were PK exposure and model-predicted steady-state area under the curve (AUCss) over an 8-week dosing interval at weeks 28 and 52, respectively. JIA ACR response and safety were also assessed. RESULTS: In total, 127 children were treated with i.v. golimumab. JIA ACR 30, 50, 70, and 90 response rates were 84%, 80%, 70% and 47%, respectively, at week 28 and were maintained through week 52. Golimumab serum concentrations and AUCss were 0.40 µg/ml and 399 µg ⋅ day/ml at week 28. PK exposure was maintained at week 52. Steady-state trough golimumab concentrations and AUCss were consistent across age categories and comparable to i.v. golimumab dosed 2 mg/kg in adults with rheumatoid arthritis. Golimumab antibodies and neutralizing antibodies were detected via a highly sensitive drug-tolerant assay in 31% (39/125) and 19% (24/125) of patients, respectively. Median trough golimumab concentration was lower in antibody-positive vs antibody-negative patients. Serious infections were reported in 6% of patients, including one death due to septic shock. CONCLUSION: Body surface area-based dosing of i.v. golimumab was well tolerated and provided adequate PK exposure for clinical efficacy in paediatric patients with active pc-JIA.ClinicalTrials.gov number NCT02277444.
引用
- Ruperto N, Brunner HI, Pacheco-Tena C, et al. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021. PMID: 33493312. doi:10.1093/rheumatology/keab021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。